

Specialty Medication Review Program

Tremfya® (guselkumab) for
Crohn's Disease, Psoriasis, Psoriatic Arthritis, & Ulcerative Colitis
(Self-Administered) or (Healthcare Professional Administered)
Rx Benefit or Medical Benefit

Complete this form and fax to:

☐ **Medical (Office Admin)**
Fax #: 1-800-306-0188
Phone #: 1-800-499-1275

If you are not **buying and billing** this medication, indicate which specialty pharmacy will be used:

☐ **Pharmacy (Self-admin)**
Fax: 1-800-956-2397
Phone: 1-800-499-1275

☐ **Accredo Health**
Fax: 1-888-773-7386
Phone: 1-866-413-4137

☐ **Walgreens Specialty Pharmacy**
Fax: 1-866-435-2173
Phone: 1-866-435-2171

Complete ALL the following Patient/Prescriber information: (Please Print)

Patient Information			
Patient Name:		Patient Phone #: ()	
Patient ID #:		Patient Birthdate:	
List Patient Allergy (If Any):			
Prescriber Information			
Prescriber Name:		Prescriber Specialty:	
Prescriber Address:			
Prescriber Phone #:		Prescriber Fax #:	
Prescriber NPI #:		Office Contact:	Extension:
If health professional administered, select treatment location:			
<input type="checkbox"/> Prescriber office		<input type="checkbox"/> Home/Homecare agency: _____	
<input type="checkbox"/> Outpatient facility		<input type="checkbox"/> Other: _____	
Servicing Prescriber NPI (if different from the ordering prescriber):			
Provide address of infusion location above for medication shipping:			
Medication/Medical and Dispensing Information			
Medication (HCPCS)	Dose	Height	Weight (lbs.)
Tremfya (J1628)	<input type="checkbox"/> 100mg SC at weeks 0 and 4, and then every 8 weeks thereafter <input type="checkbox"/> 200mg IV at weeks 0, 4, 8 then 100mg SC every 8 weeks thereafter <input type="checkbox"/> 200mg IV at weeks 0, 4, 8 then 200mg SC every 4 weeks thereafter <input type="checkbox"/> 400mg (2x200mg) SC at weeks 0, 4, 8, then 100mg SC every 8 weeks thereafter <input type="checkbox"/> 400mg (2x200mg) SC at weeks 0, 4, 8, then then 200mg SC every 4 weeks thereafter		
1. Diagnosis/ICD-10: _____			
2. Is this request for a: <input type="checkbox"/> New Start OR <input type="checkbox"/> Continuation of Therapy (recertification) Start date: _____			
3. If an induction dose is being requested, please choose how it will be administered:			
<input type="checkbox"/> IV/SC induction dose that will be obtained/administered by a healthcare professional <input type="checkbox"/> SC induction dose that will be self-administered <input type="checkbox"/> Induction dose is not being requested			
4. For all request, please choose how ongoing therapy will be administered:			
<input type="checkbox"/> Ongoing therapy will be self-administered (Pharmacy Benefit) (*Fax to the Pharmacy Dept at 1-800-956-2397) <input type="checkbox"/> Ongoing therapy will be obtained/administered by a healthcare professional (Medical Benefit) (*Fax to Medical Dept at 1-800-306-0188)			
Questions/Indications for Medical Necessity			
** See the Inflammatory CRPA Policy (Pharmacy-73) for full Prior Authorization criteria **			
1. Select One of The Following Diagnoses & must be active & moderate to severe		2. Select One of the following prescribers	
<input type="checkbox"/> Chronic Plaque Psoriasis <input type="checkbox"/> Crohn's Disease <input type="checkbox"/> Psoriatic Arthritis <input type="checkbox"/> Ulcerative Colitis <input type="checkbox"/> Other: _____		<input type="checkbox"/> Dermatologist <input type="checkbox"/> Rheumatologist <input type="checkbox"/> Gastroenterologist	

Crohn's Disease

1. If patient has had tried and failed or had an intolerance to at least one of the therapies below for at least 3 months, indicate which drug(s) have been tried (**letter of medical necessity and clinical progress notes must be submitted**):

Drug Name	Period of Use	Outcomes
<input type="checkbox"/> Methotrexate, Azathioprine, 6-mercaptopurine	Start: End:	
<input type="checkbox"/> 5-ASA products (mesalamine, sulfasalazine, etc.)	Start: End:	

Plaque Psoriasis

1. Provide % BSA affected (if less than 10%, define how this is disrupting activities of daily living: BSA % : _____)

2. If patient has failed first line drug therapy for a trial of at least 3 months, indicate which drug(s) he/she has not responded to:

Drug Name	Period of use	Outcomes
<input type="checkbox"/> Acitretin	Start: End:	
<input type="checkbox"/> Methotrexate	Start: End:	
<input type="checkbox"/> Cyclosporine	Start: End:	
<input type="checkbox"/> Medium/High Potency Steroid (provide name(s) of steroid(s) tried:_____)	Start: End:	
<input type="checkbox"/> Anthralin, Calcipotriene, or Tazarotene	Start: End:	
<input type="checkbox"/> UVB and Coal Tar	Start: End:	
<input type="checkbox"/> PUVA and Topical Corticosteroids	Start: End:	
<input type="checkbox"/> Intralesional Corticosteroid Injections	Start: End:	
<input type="checkbox"/> Other:	Start: End:	

Ulcerative Colitis

1. If patient has had tried and failed or had an intolerance to at least one of the therapies below for at least 3 months, indicate which drug(s) have been tried (**documentation of an intolerance must be submitted**):

Drug Name	Period of Use	Outcomes
<input type="checkbox"/> Methotrexate, Azathioprine, 6-mercaptopurine	Start: End:	
<input type="checkbox"/> 5-ASA products (mesalamine, sulfasalazine, etc.)	Start: End:	
<input type="checkbox"/> Cyclosporine	Start: End:	
<input type="checkbox"/> IV or oral steroids	Start: End:	

2. The patient has been diagnosed with pouchitis and has tried an antibiotic, corticosteroid enema, or mesalamine enema?

☐ Yes ☐ No

***Documentation required**

Provide any other comments/clinical justification:

***ATTACH CLINICAL NOTES RELATED TO THIS REQUEST. IF DOCUMENTATION IS NOT PROVIDED, IT MAY DELAY THE REQUEST.**

***Prescriber Signature:** _____ **Date:** _____

I certify the above is true and accurate to the best of my knowledge.